About Advanced Therapies Week:
Advanced Therapies Week USA is the key event driving the cell and gene therapy revolution, showcasing groundbreaking technologies and partnerships in drug development. Held in Dallas this January, the event offers a unique opportunity to connect with local research centers, drug developers, and CDMOs, highlighting Texas as a growing biomanufacturing hub for CGT progress.
Stop by the BIA (UK BioIndustry Association) booth 849 to chat with our OXB experts: Dr. Sébastien Ribault (Chief Business Officer), Sharmilee Patel (Head of Business Development, East Coast) and Sarah Hove (Head of Business Development, West Coast).
About Sébastien, Chief Business Officer
Dr. Sébastien Ribault joined OXB in 2022 as Chief Commercial Officer. He has over 25 years of experience across the biotechnology industry and CDMO space. Sébastien was previously at Merck KGaA, Darmstadt, Germany where he was Vice President & Head of Biologics and Viral Vector CDMO, leading the CDMO expansion project, establishing the services business case and helping to establish the Life Science Services business unit. Prior to his 17 years with Merck KGaA, Sébastien was a Gene Therapy Development Scientist at Transgene and Head of the R&D Laboratory at Hemosystem. He has a PhD in Molecular and Cellular Biology from the University of Strasbourg.
About Sharmilee, Head of US East Coast Business Development
Sharmilee Patel joined OXB as Senior Director, Business Development in 2021. She holds a Bachelor of Science from University of Alabama, Birmingham (UAB) and has over 24 years of experience in biotechnology focused on contract development, manufacturing, and testing services. Prior to joining OXB, Sharmilee worked with three different CDMOs where she focused on quality, program management, and business development for CDMOs serving multiple modalities to include microbial and mammalian derived protein therapeutics as well as tissue, cell, and gene therapies.
About Sarah, Head of US West Coast Business Development
Sarah Hove currently leads the Western US Business Development team at OXB. Prior to joining OXB in 2022, she spent 23 years at Merck KGaA, Darmstadt, Germany in business strategy, commercial, and process development leadership roles. Sarah has her Bachelors of Science degree in chemistry from University of California Santa Cruz, with a focus on physical chemistry and pharmacology.